Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT04828746 |
| Other study ID # |
IRB-20-800 |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
March 15, 2021 |
| Est. completion date |
March 2023 |
Study information
| Verified date |
January 2022 |
| Source |
Carilion Clinic |
| Contact |
Andrew Hayes, DO |
| Phone |
540-682-0259 |
| Email |
ajhayes[@]carilionclinic.org |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
The standard way to identify landmarks in the spine before inserting a needle for a lumbar
puncture is to feel by touch. The purpose of this research is to determine if doing an
ultrasound to identify landmarks before performing a lumbar puncture will improve the
first-time success rate of the needle insertion in pediatric patients.
Description:
Subjects will be identified for the study after meeting inclusion & exclusion criteria. Part
of said criteria is that the patient will medically require a lumbar puncture (LP) to be
completed for their medical care and the patient is currently located in the Carilion Roanoke
Memorial Hospital (CRMH) Pediatric Emergency Department, Pediatric Ward, or Pediatric
Intensive Care Unit. After the study team member identifies a patient who meets the criteria
and obtains the necessary consent/assent(s) the practitioner will then load the preset
procedure note into the electronic medical record. In this procedure note, there will be a
link to REDCap (a secure data collection tool) where the study team member will enter the
patient's medical record number and date of birth. The participant will then be randomized to
either the standard of care/ control group (palpation only lumbar puncture) or the
experimental group (lumbar puncture after ultrasound-guided (US) skin marking) via REDCap.
REDCap will be set to randomize participants via block randomization to the desired total
number of 60 (30 in each control and experiential groups), and no study team member/
practitioner will have access to the set block randomization parameters in REDCap.
Regarding sedation versus analgesia (performed for standard of care reasons and not affected
by the research study), the decision on what is best and needed for the patients will be up
to the performing practitioner in both groups. This ranges from superficial skin numbing
cream and sucrose gel (for neonates) to lidocaine injections to oral or IV medications for
pain/anxiety to full procedural sedation; or a combination of any of these methods. This will
be entirely up to the performing practitioner as the methods used can vary greatly from
patient to patient based on a multitude of factors. If procedural sedation is required then
often another attending physician must be present in order to administer the sedating
medications but this individual is not part of the study and will obtain their own consent
for sedation as applicable as per Carilion Clinic policy. The agent(s) of choice will be
clearly documented in the procedure note so this information can be taken into consideration
when performing data analysis. All sedation v analgesia will take place prior to beginning
the procedure. Once the practitioner is ready to begin they will start a timer to properly
keep time as to the duration of the entire procedure.
The practitioner performing the lumbar puncture procedure will either be a study team member
or another practitioner who is under the direct supervision of a study team member (e.g.
advanced care practitioner under an attending, a junior resident under a senior resident).
The study team member will supervise/perform the procedure as indicated to not only ensure
the safety of patients but to make sure proper protocol is followed.
After analgesia v sedation is administered, if the participant is in the standard of care
group, the practitioner will then position the patient in the best position they believe is
needed to obtain the cerebral spinal fluid (CSF) sample. This is typically sitting upright or
having the patient lying down on their side (with the latter being more common). The
practitioner will then palpate the area they feel is the best to insert the spinal needle to
collect the sample. The gap that is being palpated is typically between the 3rd and 4th or
the 4th and 5th lumbar vertebrae. Following this, the practitioner will then don sterile
gloves, and clean the patient's back with betadine or chlorhexidine as per their discretion.
The spinal needle will then be inserted into the spinal interspace, the stylet from the
needle will be removed, and the fluid will be collected. The amount of fluid that will be
collected varies based on the patient's age as well as the testing that is deemed clinically
necessary. Typically 1-3 milliliters of CSF will be collected in each of the 3-4 tubes that
are provided in the LP kit that is used for the procedure. After the fluid is collected, the
needle will then be removed and pressure will be held on the insertion site to ensure no
bleeding or CSF leakage. When bleeding or fluid leakage has halted the procedure is then
completed and the timer is stopped. The time it takes to perform this procedure varies
greatly with different practitioners and patients but is typically completed within 15-60
minutes.
After analgesia v sedation is administered, if the participant is in the experimental group
(use of ultrasound), the practitioner will then position the patient in the best position
they believe is needed to obtain the cerebral spinal fluid (CSF) sample. This is typically
sitting upright or having the patient lying down on their side (with the latter being more
common). The practitioner will then use a portable, point-of-care US machine in order to
identify the best interspace to obtain the sample. This involves using a small amount of US
gel (a non-toxic, water-based substance used to improve sound waves and therefore picture
quality when performing the US) and the actual US probe on the patient's back. After the
desired space is identified in the sagittal and transverse planes with the US machine, a
small mark will be placed on the patient using a surgical pen (a marker similar to a
"sharpie" but is safe for use on human skin and will wash off in 1-2 days). The desired space
that is being identified is typically between the 3rd and 4th or the 4th and 5th lumbar
vertebrae. Following this, the practitioner will then wipe the US gel off the patient's back,
don sterile gloves, and clean the patient's back with betadine or chlorhexidine as per their
discretion. The spinal needle will then be inserted into the spinal interspace that was
identified and marked as noted previously, the stylet from the needle will be removed, and
the fluid will be collected. The amount of fluid that will be collected varies based on the
patient's age as well as the testing that is deemed clinically necessary. Typically 1-3
milliliters of CSF will be collected in each of the 3-4 tubes that are provided in the LP kit
that is used for the procedure. After the fluid is collected, the needle will then be removed
and pressure will be held on the insertion site to ensure no bleeding or CSF leakage. When
bleeding or fluid leakage has halted the procedure is then completed and the timer is
stopped. The time it takes to perform this procedure varies greatly with different
practitioners and patients but we anticipate it taking between 25-70 minutes. The extra time
allotted is due to the use of the US, but how much time exactly it will take is not fully
known, and in fact, it may not add time as compared to the control population but this will
need to be investigated further during data analysis. There is potential for a patient to be
under sedation (as discussed above) for a longer time if using US rather than the standard of
care palpation only, but this is currently unknown.
CSF will be sent to the lab and analyzed with the tests that are deemed needed by the
practitioner. In general, it is commonplace for a "CSF Cell Count & Differential" to be
ordered on all CSF samples as this is a baseline test of the sample. The data provided from
this test will be analyzed by research team members via the medical record but the actual
sample itself or what additional tests are ordered will in no way be impacted by the
research. Specifically, this test tells the study team member how many red blood cells are
present in the CSF. With some exceptions, the fewer red blood cells that are present in the
CSF fluid is indicative of a procedure that was able to be performed smoothly, efficiently,
and without multiple attempts. The CSF from the first tube will be used for the "CSF Cell
Count & Differential", which again is commonplace. In some, uncommon instances (for various
reasons including dehydration, failed LP attempt) only a small amount of CSF can be obtained.
Should this be the case, the practitioner will decide what tests are needed on the small CSF
sample. Data from the procedure (excluding the "CSF Cell Count & Differential" if there was
not enough sample to run this test) may still be used in data analysis so the participant
will still be enrolled in the study. An instance in which this may occur is on a dehydrated
child where there are suspicions of meningitis. In this case, the most crucial test to run on
the CSF is a bacteria or viral culture. Again the cell count and differential are still very
helpful and standard to order on these samples but the first priority goes to the culture if
there was only a small sample that was able to be obtained.
The amount of time needed to access the patient's medical record by a study team member after
the procedure and lab test completion is approximately 30 minutes per patient. In general,
the patient's age, weight, height, the results of the "CSF Cell Count & Differential" lab
testing, the level of the practitioner but not their identity (ie resident v attending), and
procedure notes will be specifically accessed for collection and analyzing. This will be done
in a HIPAA compliant manner (e.g. private, secure, password-protected computers, internet
access, and databases). At least weekly a member of the study team will be accessing patient
charts (with the HIPAA data provided by REDCap) in order to extract the de-identified data
required and place it in a secure spreadsheet. After the de-identified data is collected, the
participant's medical chart, as well as PHI, will not need to be accessed again. No follow-up
will be needed for the purposes of this study.
